The Annual General Meeting of Tripep AB
The Annual General Meeting of Tripep AB The Annual General Meeting of Tripep AB was held in Stockholm, Sweden, on 25 March 2004. Annual Report and discharge from liability The company's Income Statement and Balance Sheet were approved and the Board of Directors and Chief Executive Officer were discharged from liability for the financial year 2003. Election of Board of Directors Rolf L. Nordström, Anders Vahlne and Matti Sällberg were appointed to the Board of Directors, (all re-elected), as were William W. Hall and Yiming Shao (both elected). Erik Nerpin declined re-election. Parallel listing on the AIM The Annual General Meeting resolved to authorise the Board of Directors to apply for a parallel listing of Tripep's shares on the London Stock Exchange AIM (Alternative Investment Market). Authorisation regarding share buy-backs The Board of Directors was authorised to resolve on the transfer of the company's holdings of 1,356,345 of its own shares on the Stockholm Stock Exchange, and if applicable, the London Stock Exchange (AIM), or in some other manner, including the right to resolve waiving shareholders' preferential rights, and with payment possible through means other than cash, in the period until the next Annual General Meeting. Authorisation to resolve on new issues The Board of Directors was authorised to resolve on the issue of an aggregate total of 1,400,000 new shares against cash payment and/or with a decision of payment in kind or off-set, or according to other terms and conditions, and thereby, being able to waive shareholders' preferential rights. Nomination Committee The Annual General Meeting resolved to appoint a Nomination Committee comprising the Chairman of the Board Rolf L. Nordström, Peter Horal and Bo Svennerholm. Board meeting following election Rolf L. Nordström was re-appointed Chairman of the Board at the Board meeting following election. For information, please contact: Rolf L Nordström, Chairman of the Board, Tripep AB Tel:+442078398686, mobile phone: +447776137400 Email: rolf.l.nordstrom@btinternet.com Tripep is a biotech research company that develops and commercialises candidate drugs based on patented and patent-pending technologies: -research and development of alphaHGA, a HIV-inhibiting drug, -preclinical research focusing on the development of therapeutic and prophylactic vaccines against HIV and hepatitis C, and the RAS® technology platform. -producing vaccines against influenza, allergies and Alzheimer's disease through associated company VLP Biotech Inc. More details on Tripep's technologies are available at its Website: www.tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2004/03/26/20040428BIT20390/wkr0006.pdf http://www.waymaker.net/bitonline/2004/03/26/20040428BIT20390/wkr0008.doc